Infusion services make up a roughly $150 billion market in the U.S., and underpin the financial stability of major service lines, especially oncology. Historically, health systems have enjoyed strong volumes, favorable reimbursement, and access to 340B discounts that keep their infusion business profitable. But rising competition, payer and employer driven site of care shifts, and looming policy changes are putting pressure on what many leaders have relied on as a stable, margin accretive business.

In this episode, host Abby Burns sits down with Advisory Board expert Chloe Bakst to break down what’s actually happening in the infusion market — and why every health system leader should be paying closer attention. Together, they explore how new competitors are capturing leakage you may not even see, how payers and employers are steering patients away from hospital outpatient departments, and how upcoming 340B reforms and Medicare drug price negotiations could reshape the economics of infusion over the next three years. Chloe also shares the strategies forward thinking systems are using to protect their infusion business and prepare for rapidly emerging headwinds.

We’re here to help:

Webinar | The top trends in today’s infusion market
Tool | Market Scenario Planner
Ready-to-Use Resource | Policy Scenario Impact Calculator
Expert Insight | The 3 trends reshaping the specialty drug pipeline today
Podcast | 270: Service line snapshot: What every health leader needs to know

Webinar | Join Optum Advisory experts at this upcoming webinar to learn how optimizing patient access unlocks the value of digital innovations and drives long-term sustainability.

Expert Insight | How data-driven risk reduction protects patients and providers

A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

287: Infusion revenues are under threat: What to watch and how to prepare

Radio Advisory